Ashland Stock Price, News & Analysis

Ashland (NYSE: ASH) has announced its board of directors has declared a quarterly cash dividend of $0.415 per share, marking a 2.5% increase from the previous quarter. The dividend will be paid on June 15, 2025, to stockholders of record as of June 1, 2025. As of April 30, 2025, Ashland reported 45,696,225 outstanding shares of common stock.

Ashland Inc. (NYSE: ASH) announced significant executive leadership changes. Kevin Willis, senior vice president and CFO, will depart on May 16, 2025, after a 38-year tenure with the company. The board appointed William C. Whitaker, current vice president of finance and director of investor relations, as interim CFO. Additionally, Samuel A. Richardson was appointed as vice president, controller and principal accounting officer.

Whitaker, 36, has been with Ashland since 2015, holding various positions in corporate development, treasury, FP&A, and investor relations. Richardson, 46, has served as controller since January 2020 and has extensive accounting experience with the company since 2008.

Ashland reported second quarter fiscal 2025 results with sales of $479 million, down 17% year-over-year. The decline includes a 12% reduction from Portfolio Optimization initiatives and a 5% organic decrease.

Key financial metrics include:

• Income from continuing operations: $30 million ($0.63 per diluted share)
• Net income: $31 million ($0.65 per diluted share)
• Adjusted EBITDA: $108 million, down 14% from prior year
• Operating cash flow: $9 million

The company's segments showed mixed performance: Life Sciences sales fell 23% to $172 million, Personal Care decreased 14% to $146 million, Specialty Additives declined 15% to $134 million, and Intermediates dropped 8% to $37 million. Despite challenges, cost savings initiatives are on track, with Life Sciences and Personal Care maintaining EBITDA margins above 30%. The company has revised its full-year fiscal 2025 outlook due to weakening macroeconomic conditions.

Ashland Inc. (NYSE: ASH) has scheduled its second-quarter fiscal 2025 earnings release for April 30, 2025, at approximately 5 p.m. ET. The company will host a live webcast with securities analysts on May 1, 2025, at 10 a.m. ET.

Key executives participating in the presentation include Chair and CEO Guillermo Novo, CFO Kevin Willis, and several senior vice presidents leading different business segments. The webcast will feature an executive summary and detailed remarks, accompanied by a slide presentation available on the company's investor relations website.

Participants can access the call via phone through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. The webcast and supporting materials will be accessible through Ashland's Investor Relations website and will remain archived for 12 months following the live event.

Ashland has completed a $10 million expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil, with a ribbon-cutting ceremony scheduled for April 4, 2025. The investment aims to meet growing market demand for coated tablets in Latin America, where consumption grew 4.3% annually between 2019-2023, with Brazil reaching 5.7% yearly growth.

The expansion includes modernization of microbial protection equipment at the R&D laboratory in São Paulo, following previous investments in Ireland and China. The new state-of-the-art facilities enhance Ashland's capabilities in tablet coatings application, color matching, stability, and quality evaluation. Local employees received specialized training at US headquarters to ensure optimal performance.

In 2023, Ashland introduced seven new platform technologies focused on sustainable innovations in personal care, pharmaceuticals, and coatings sectors. The company has already launched several patented innovations from their Transformed Vegetable Oils and Super Wetters platforms.

Ashland Inc. (NYSE: ASH) announces its upcoming Innovation Day for analysts and investors, scheduled for May 29, 2025, at their Bridgewater, New Jersey facility. The event will showcase enhanced capabilities and expanded applications of Ashland's scalable technology platforms.

The event, running from 9:00 AM to 11:30 AM ET, will feature presentations from key leadership including Chair and CEO Guillermo Novo and Chief Technology Officer Osama Musa. Participants can attend either in person or via live webcast, with in-person attendees enjoying additional benefits including:

• Lab tours highlighting applications in Life Sciences, Personal Care, and Specialty Additives
• Direct engagement with senior leadership during Q&A sessions
• Networking opportunities with business line leaders and scientists during a luncheon

In-person activities will conclude at approximately 2:00 PM ET. The presentation materials will be available on Ashland's investor website, with replay access for 12 months following the event.

Ashland Inc. (NYSE: ASH) has completed the sale of its Avoca business to Mane on March 14, 2025. The Avoca business, which represents the final entity from Ashland's previous Pharmachem acquisition, specializes in producing sclareolide (a fragrance fixative) and offers contract manufacturing capabilities through facilities in North Carolina and Wisconsin.

While financial terms were not disclosed, the transaction marks a strategic divestment for Ashland. The deal transfers Avoca's manufacturing facilities and its workforce to Mane, whose CEO Samantha Mane expressed commitment to ingredient production through this acquisition. Squire Patton Boggs served as Ashland's legal advisor for the transaction.

Ashland Inc. (ASH) reported Q1 fiscal 2025 financial results with sales of $405 million, down 14% year-over-year. The decline includes an 11% reduction ($50 million) from Portfolio Optimization initiatives. The company reported a net loss of $165 million, or $3.50 per diluted share, compared to net income of $26 million in the prior year.

Adjusted EBITDA was $61 million, down 13% from the prior year, primarily due to Portfolio Optimization, reduced pricing, and increased expenses. The company maintains its full-year fiscal 2025 outlook, expecting sales between $1.90-2.05 billion and Adjusted EBITDA of $430-470 million.

Ashland signed a definitive agreement to sell its Avoca business to Mane and is implementing a $30 million cost reduction plan to offset stranded costs from the nutraceutical business sale.

Ashland (NYSE: ASH) has announced that its board of directors has declared a quarterly cash dividend of $0.405 per share on the company's common stock. The dividend will be paid on March 15, 2025, to stockholders of record as of March 1, 2025. The company reported 47,182,862 outstanding shares of common stock as of December 31, 2024.